Bora Eldem

Bora Eldem

Auto-generated profile, based on publicly available information

Bora Eldem

Department of Ophthalmology, Hacettepe University School of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2020 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
ABAta Baytaroğlu
Ata Baytaroğlu
SKSibel Kadayifçilar
Sibel Kadayifçilar
AAAbdullah Agin
Abdullah Agin
ÖDÖzge Deli̇kTaş
Özge Deli̇kTaş
SDSelcan Demir
Selcan Demir
BEBora Eldem
Bora Eldem
Background/purpose: To assess EDI-OCT (enhanced depth imaging optical coherence tomography) of choroid for inflammatory signs in children with polyarteritis nodosa (PAN) and adenosine deaminase-2 deficiency (DADA-2). Methods: In this cross-sectional study conducted between June 2017 and September 2018, we evaluated children diagnosed with PAN (n = 11) and DADA-2 (n = 4) and an age- and sex-matched control group (n = 15). Demographic and laboratory data were retrospectively analyzed from patient charts. Disease activity was assessed using the pediatric vasculitis activity score (PVAS). Choroidal images were obtained with spectral domain-OCT to measure choroidal thickness (ChT) at 5 points (750 and 1500 μm from the foveal center in the temporal and nasal quadrants and beneath the fovea), and to calculate the total subfoveal choroidal area (TCA), luminal area (LA), stromal area (SA), and the choroidal vascularity index (CVI). Results: The median (min-max) age was 8 (4–16) years in PAN patients, 6 (5–16) years in DADA-2 patients and 8 (8–10) years in control group at the OCT visit (p = 0.214). The ChT at 3 points and the TCA, LA, and SA were higher in children with both PAN and DADA-2 patients compared to those of the control group (p < 0.0001, p = 0.049, p = 0.007, p = 0.007, p = 0.006, p = 0.033, respectively). The CVI was similar in both groups. No association was observed between the OCT findings, PVAS, and the erythrocyte sedimentation rate, and serum leukocyte and C-reactive protein levels. Conclusion: Similar CVI scores were obtained from PAN and DADA2 patients under treatment and from healthy controls. Increased subfoveal ChT without any other signs of ocular involvement may suggest choroidal thickening as a sign of mild subclinical inflammation.

16 October 2019 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
VDVincent Daien
Vincent Daien
BEBora M. Eldem
Bora M. Eldem
JTJames S. Talks
James S. Talks
JKJean-Francois Korobelnik
Jean-Francois Korobelnik
PMPaul Mitchell
Paul Mitchell
JCJoao Carrasco
Joao Carrasco
Background: Real-world data (RWD) has been a valuable addition to the scientific literature regarding treatment pathways, clinical outcomes and characteristics of patients with retinal diseases in recent years. Registries, observational studies and patient databases are often used for real-world research. However, there is limited information for each data source on the design, consistency, data captured, limitations and usability for assessing research questions. Using a systematic approach, we identified RWD sources for patients with retinal diseases and assessed them for completeness of data relating to different outcomes. Methods: A systematic literature review was carried out to identify RWD sources for patients with retinal disease. Potentially relevant articles published between 2006 and 2016 were screened following electronic searches in Embase and MEDLINE. Congress and supplementary searches were undertaken to identify RWD sources that may not be referenced in full publications. For each data source, availability and quantity of data on baseline status, clinical outcomes, treatment and management, safety, and patient-reported and economic burden were assessed using a bespoke completeness assessment tool based on International Consortium for Health Outcomes Measurement guidelines for macular degeneration. Completeness of data for each area of interest in each data source was assessed and rated using a ‘good–moderate–poor’ rating system based on availability and quantity of available data. Each data source was then given an overall score based on its score for each of the 7 areas of interest. Results: A total of 128 RWD sources from 32 countries were identified. Of the identified sources, 64 sources from 16 countries of interest were analyzed. Most of these sources provided information on baseline status and clinical outcomes and treatment, but few collected data on economic and patient-reported burden. Of the RWD sources analyzed, 10 scored highly in the overall completeness assessment, collecting data on most or all of the areas of interest; these sources are considered to be robust data sources for performing ophthalmology real-world studies. Conclusions: The study provides a comprehensive list of RWD sources for patients with retinal disease, many of which will be useful for conducting real-world studies in the field of ophthalmology.

6 December 2003
Verified
Journal Article
Closed access
SKSibel Kadayifçilar
Sibel Kadayifçilar
BEBora Eldem
Bora Eldem
BTBurak Tumer
Burak Tumer

27 August 2014 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
BEBora M. Eldem
Bora M. Eldem
GMGulipek Muftuoglu
Gulipek Muftuoglu
STSeyhan Topbaş
Seyhan Topbaş
MÇMehmet Çakir
Mehmet Çakir
SKSibel Kadayifcilar
Sibel Kadayifcilar
TGthe SALUTE study group
the SALUTE study group

3 March 2018 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Open access
PDF file
BEBora Eldem
Bora Eldem
TLTimothy Y. Y. Lai
Timothy Y. Y. Lai
NNNor Fariza Ngah
Nor Fariza Ngah
BVBrendan Vote
Brendan Vote
HYHyeong Gon Yu
Hyeong Gon Yu
NCNathan J. Clunas
Nathan J. Clunas
Purpose To describe intravitreal ranibizumab treatment frequency, clinical monitoring, and visual outcomes (including mean central retinal thickness [CRT] and visual acuity [VA] changes from baseline) in neovascular age-related macular degeneration (nAMD) in real-world settings across three ranibizumab reimbursement scenarios in the Middle East, North Africa, and the Asia–Pacific region. Methods Non-interventional multicenter historical cohort study of intravitreal ranibizumab use for nAMD in routine clinical practice between April 2010 and April 2013. Eligible patients were diagnosed with nAMD, received at least one intravitreal ranibizumab injection during the study period, and had been observed for a minimum of 1 year (up to 3 years). Reimbursement scenarios were defined as self-paid, partially-reimbursed, and fully-reimbursed. Results More than three-fourths (n = 2521) of the analysis population was partially-reimbursed for ranibizumab, while 16.4% (n = 532) was fully-reimbursed, and 5.8% was self-paid (n = 188). The average annual ranibizumab injection frequency was 4.1 injections in the partially-reimbursed, 4.7 in the fully-reimbursed and 2.6 in the self-paid populations. The average clinical monitoring frequency was estimated to be 6.7 visits/year, with similar frequencies observed across reimbursement categories. On average, patients experienced VA reduction of −0.7 letters and a decrease in CRT of −44.4 μm. The greatest mean CRT change was observed in the self-paid group, with −92.6 μm. Conclusions UNCOVER included a large, heterogeneous ranibizumab-treated nAMD population in real-world settings. Patients in all reimbursement scenarios attained vision stability on average, indicating control of disease activity.

11 October 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AAAbdullah Agin
Abdullah Agin
SKSibel Kadayıfçılar
Sibel Kadayıfçılar
ABAta Baytaroğlu
Ata Baytaroğlu
ÖDÖzge Deliktaş
Özge Deliktaş
SDSelcan Demir
Selcan Demir
BEBora Eldem
Bora Eldem